The Foundation Dedicated to Discovering a Cure for Neuroendocrine Cancer

Caring for Carcinoid Foundation
Sign-up for our e-Newsletter.

Reasons to be Hopeful
Newly Diagnosed?
Create Change Join Team CFCF
Clinical trials
CFCF Photo
CFCF Photo
Make a Difference - Get Involved Today
The latest in carcinoid and pancreatic neuroendocrine cancer research

See how you can make a difference
Donate Now

10/29 CFCF Launches Major Immunotherapy Initiative

After reviewing the research with our Board of Scientific Advisors and consulting our Board of Directors, we are thrilled to announce that we are embarking upon a major research initiative in immunotherapy. A treatment that uses the body’s own immune system to fight cancer, immunotherapy has led to dramatic results for some patients with other forms of cancer. We are eager to test the potential of immune-based therapy to provide similar breakthroughs for patients with neuroendocrine cancers and have brought leading immunotherapy experts on board to do so. Through a clinical trial and the development of breakthrough immunotherapy technology, we will be focusing on the effects of immunotherapy for carcinoid and pancreatic neuroendocrine tumors.

10/24 UPenn Patient Education Conference

Focus on Neuroendocrine Tumors: Patient & Caregiver Conference

Hilton Hotel
4200 City Avenue
Philadelphia, PA

Gain knowledge and take action by getting important information from our expert faculty. Receive hope and support by networking with others. This free patient education conference is being presented jointly by Penn's Abramson Cancer Center and the Caring for Carcinoid Foundation.

Conference Co-Chairs:
David Metz, MD - Gastroenterology Division
Debbie Cohen, MD - Renal, Electrolyte and Hypertension Division
Ronald Holander - Executive Director, Caring for Carcinoid Foundation

Click here to view the agenda.

Register now!

07/18 New Article Suggests Effectiveness of Drug for Prolonged Progression-Free Survival

An article published in New England Journal of Medicine suggests the effectiveness of Somatuline(R) Depot (R) (lanreotide) in prolonged “progression-free survival” for more than 65 percent of patients who took it in a late-stage clinical trial, conducted at 48 sites in 14 countries.



Latest Video

Check out the CFCF video library.


Ron's Blog

Read the latest blog from CFCF's Executive Director.


Lauren's Blog

Read the latest blog from CFCF's Director of Research.

Seal Exchange      


Check back soon for more events!

Connect with CFCF online:

The passing of Steve Jobs is a powerful reminder of the need for funding for research to find a cure for Pancreatic Neuroendocrine and other neuroendocrine cancers.